Advanced Biotherapy

Advanced Biotherapy was a clinical-stage biotechnology company focused on developing cytokine-neutralizing therapies for autoimmune and inflammatory diseases. The company's primary research centered on the use of monoclonal antibodies to inhibit interferon gamma and tumor necrosis factor, which are key drivers of inflammation in conditions like multiple sclerosis and rheumatoid arthritis. Its lead candidate, an anti-interferon gamma antibody, reached Phase 2 clinical trials for multiple sclerosis. After facing financial and clinical challenges, the company completed a reverse merger with Kalytera Therapeutics in December 2016, transitioning its focus to cannabinoid-based medicines.